Concord Medical Files 2022 Annual Report on Form 20-F
Concord Medical Services Holdings Limited (NYSE: CCM) announced the filing of its annual report on Form 20-F for the fiscal year ended December 31, 2022. This report is accessible on both Concord Medical's investor relations website and the SEC's website. Concord Medical specializes in oncology services, providing a full cycle of cancer diagnosis, treatment, education, and prevention via a network of radiotherapy and diagnostic imaging centers in China. The company emphasizes the deployment of advanced technology, including proton therapy systems, to enhance cancer care quality and accessibility. Shareholders can request a hard copy of the report free of charge.
- Successful filing of Form 20-F for fiscal year 2022, ensuring compliance with SEC regulations.
- Expansion of cancer treatment services through a network of advanced healthcare facilities in China.
- None.
BEIJING, April 19, 2023 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensive network of radiotherapy and diagnostic imaging centers in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022 (the "Annual Report") with the U.S. Securities and Exchange Commission. An electronic copy of the Annual Report can be accessed on Concord Medical's investor relations website at http://ir.ccm.cn and on the SEC's website at www.sec.gov. Shareholders may receive a hard copy of the Annual Report free of charge upon request. Requests should be submitted to http://ir.ccm.cn.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
View original content:https://www.prnewswire.com/news-releases/concord-medical-files-2022-annual-report-on-form-20-f-301801615.html
SOURCE Concord Medical Services Holdings Limited
FAQ
What did Concord Medical announce on April 19, 2023?
Where can I access Concord Medical's 2022 annual report?
What services does Concord Medical offer?
What technology does Concord Medical use in its cancer treatment facilities?
How can shareholders receive a hard copy of Concord Medical's annual report?
